DUBLIN--(BUSINESS WIRE)--Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today announced financial guidance for its fiscal year ending September 25, 2015. For fiscal 2015, Mallinckrodt’s annual net sales are expected to be in the range of $3.65 billion to $3.75 billion on an operational basis, which excludes the impact of fluctuations in foreign currency exchange rates1. Net sales for the company’s Specialty Pharmaceutical segment are expected to be in the range of $2.87 billion to $2.92 billion. This forecast includes full fiscal year net sales contributions from H.P. Acthar® Gel and OFIRMEV®, two leading branded products in its Specialty Pharmaceuticals segment. Net sales for the company’s Global Medical Imaging segment are expected to be in the range of $760 million to $800 million.
Help employers find you! Check out all the jobs and post your resume.
